GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Intec Pharma Ltd (XTAE:NTEC) » Definitions » Short-Term Debt

Intec Pharma (XTAE:NTEC) Short-Term Debt : ₪0.00 Mil (As of Mar. 2021)


View and export this data going back to 2010. Start your Free Trial

What is Intec Pharma Short-Term Debt?

Intec Pharma's Short-Term Debt for the quarter that ended in Mar. 2021 was ₪0.00 Mil.


Intec Pharma Short-Term Debt Historical Data

The historical data trend for Intec Pharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intec Pharma Short-Term Debt Chart

Intec Pharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Short-Term Debt
Get a 7-Day Free Trial - - - - -

Intec Pharma Quarterly Data
Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21
Short-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Intec Pharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.


Intec Pharma Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Intec Pharma's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.


Intec Pharma (XTAE:NTEC) Business Description

Traded in Other Exchanges
N/A
Address
12 Hartom Street, Har Hotzvim, Jerusalem, ISR, 9777512
Intec Parent Inc, formerly Intec Pharma Ltd is a clinical-stage biopharmaceutical company based in Israel. The company is focused on research and development and clinical trials. The company develops formulations of drugs using its proprietary gastric retention technology, the Accordion Pill. Accordion Pill is an oral drug delivery system that is designed to improve the efficacy and safety of existing drugs and drugs in development by utilizing efficient gastric retention. Accordion Pill Carbidopa/Levodopa or AP-CDLD is being developed by the company for the indication of treatment of Parkinson's disease.